CT 5300 acquires head and whole-body cross-sectional CT images for diagnosis in adult and pediatric patients and supports low-dose lung-cancer screening under approved protocols.
Clinical role
Diagnostic CT acquisition, reconstruction, review, and protocol-governed low-dose lung-cancer screening.
Images and patients
CT/CTA · Multi-region
Key limitation
The screening must be performed within the established inclusion criteria of programs or protocols approved and published by a governmental body or professional medical society. Precise Image has not been validated for lung cancer screening indications.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Required inputX-ray transmission data taken at different angles and planes.
Output and human actionCross-sectional images of the body taken at different angles and planes.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
CT 5300 acquires head and whole-body cross-sectional CT images for diagnosis in adult and pediatric patients and supports low-dose lung-cancer screening under approved protocols.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The screening must be performed within the established inclusion criteria of programs or protocols approved and published by a governmental body or professional medical society. Precise Image has not been validated for lung cancer screening indications.
Exact FDA submission
Checked 2026-09-19
The replacement uses the packet's explicit lung-screening boundary and Precise Image validation limitation.
K232491 describes manufacturer electrical, radiation, image-quality, dose, software, and system validation. Current vendor phantom claims provide evaluation inputs but should retain their reconstruction, dose, and object-size conditions.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K232491 describes manufacturer electrical, radiation, image-quality, dose, software, and system validation. Current vendor phantom claims provide evaluation inputs but should retain their reconstruction, dose, and object-size conditions.
Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K232491 FDA performance package for CT 5300
DesignManufacturer bench, phantom, image-quality, dose, software, electrical-safety, and system verification
PopulationRepresentative adult and pediatric head and body CT protocols, including approved low-dose lung screening
Scopeexact submission
Tested versionCT 5300 cleared in K232491
IndependenceSponsor or vendor study
K232491
Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
2 reviewed FDA recall records in the 2026-09-02 openFDA snapshot natively identify K232491. Read the model- and version-scoped events and confirm affected-unit and correction status with the manufacturer. FDA recall Z-0376-2026 affects CT 5300 software 5.1.0.X and 5.1.1.X and describes six motion, dose-setting, ECG-file, orientation, preview-display, and manual-ROI issues that could produce unusable imaging, additional exposure, or rescanning. FDA lists the recall as open and classified. FDA recall Z-0882-2026 affects CT 5300 software versions 4.5, 5.0, and 5.1 because improperly tightened heat-exchanger screws after replacement could allow a component to detach inside the rotating scanner. FDA lists the recall as open and classified.
FDA source
Exact product version
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact CT 5300 model and software-version match. Review the full FDA event, installed version, field correction, and local exposure to each of the six conditions.
Exact CT 5300 model and software-version match. Confirm whether the tube heat exchanger was replaced and whether the inspection or correction was completed.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: X-ray transmission data taken at different angles and planes.
Scope: Exact FDA submission. This is the packet's direct description of the reconstructed CT input.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM and IHE integration is documented for current Philips CT products; test exact software, worklist, PACS, dose-report, reconstruction, and advanced-object interoperability.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Cross-sectional images of the body taken at different angles and planes.
Scope: Exact FDA submission. The exact device description states this output; the current dose and examination-information wording is not a direct packet output statement.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Cross-sectional images of the body taken at different angles and planes.
Scope: Exact FDA submission. The exact device description states this output; the current dose and examination-information wording is not a direct packet output statement.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM and IHE integration is documented for current Philips CT products; test exact software, worklist, PACS, dose-report, reconstruction, and advanced-object interoperability.
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.
Only qualified ct technologists and physicians trained in diagnostic ct and protocol selection. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Vendor image-quality and dose claims are based on stated phantom comparisons and are not guaranteed patient outcomes. Verify pediatric protocols, lung-screening eligibility, dose monitoring, cardiac options, and installed software.
DICOM and IHE integration is documented for current Philips CT products; test exact software, worklist, PACS, dose-report, reconstruction, and advanced-object interoperability.
exact submission · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Vendor image-quality and dose claims are based on stated phantom comparisons and are not guaranteed patient outcomes. Verify pediatric protocols, lung-screening eligibility, dose monitoring, cardiac options, and installed software.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Vendor image-quality and dose claims are based on stated phantom comparisons and are not guaranteed patient outcomes. Verify pediatric protocols, lung-screening eligibility, dose monitoring, cardiac options, and installed software.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact packet identifies the device as a Computed Tomography X-Ray System; it does not establish the dossier's CT/CTA value. Controlled directory display reconciled from exact FDA wording: Computed Tomography X-Ray System. -> CT/CTA.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
9Source classes checked
0Awaiting review PubMed leads
5Awaiting review trial leads
0Unreviewed FDA recall leads
Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 5 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. 5 FDA recall candidates were manually reviewed: 2 published and 3 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 5 postmarket candidate records; 5 have been reviewed (2 published, 3 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Intended users: Withdrawn - checked 2026-09-19 - Exact FDA submission
Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: NAEOTOM Alpha.Peak, Alpha, Alpha.Pro, and Alpha.Prime are photon-counting CT systems for diagnostic cross-sectional imaging, treatment and interventional support, low-dose lung-cancer screening under approved protocols, and radiation-therapy planning.
Authorized purpose: NAEOTOM Alpha with syngo CT VB10 provides photon-counting CT for diagnosis, treatment and interventional support, and approved low-dose lung screening; this submission explicitly does not support radiation-therapy planning.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.